Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.75 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.74 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.64 |
| ▸ | CETP | P11597 | 4/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658827 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL6141077 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL3190081 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL6662705 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL21660329 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL22910990 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL21581283 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL22911004 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL21581286 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A | |
| SCHEMBL21428456 | 1.00 | MEN1 (1.00) | MEN1KMT2AASAH1DEGS1PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116568319-A | Method for reversing hepatic steatosis | 布莱特西德公司 | 2023-08-08 | — | — | CN | claimed |
| US-20250205262-A1 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-06-26 | — | — | US | disclosed |
| CN-119630391-A | Sphingolipid-loaded nanobiological formulation for immunomodulation | 西奈山伊坎医学院 | 2025-03-14 | — | — | CN | disclosed |
| EP-4499052-A2 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | Icahn School of Medicine at Mount Sinai (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4465976-A1 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | Brightseed, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-119013005-A | Use and method for promoting mitochondrial mass and function enhancement | 布莱特西德公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240374546-A1 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | BRIGHTSEED INC (US) | 2024-11-14 | — | — | US | disclosed |
| WO-2023192956-A2 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4228667-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | Brightseed, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116568319-A | Method for reversing hepatic steatosis | 布莱特西德公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023141427-A1 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | BRIGHTSEED, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20220362182-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2022-11-17 | — | — | US | disclosed |
| US-11479802-B2 | Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family | REGENERON PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022081567-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | BRIGHTSEED, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2019185038-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | 中国医学科学院基础医学研究所 | 2019-10-03 | — | — | WO | disclosed |
| EP-0920852-B1 | Keratin fiber strengthening agent and method for strengthening keratin fiber | TAKASAGO PERFUMERY CO LTD (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-6379659-B1 | APPLYING (2S,3R)-2-ACYLAMINOALKANE-1,3-DIOL TO FIBER | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-04-30 | — | — | US | disclosed |
| EP-0920852-A2 | Keratin fiber strengthening agent and method for strengthening keratin fiber | Takasago International Corporation (JP) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205262-A1 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | APOB, APOL1, SGMS1 | MEN1 2648/4885KMT2A 3630/4885ASAH1 159/4885 |
| US-20220362182-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | FABP1, CPT1A, LIPC | MEN1 4778/4885KMT2A 2645/4885ASAH1 296/4885 |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | MEN1 3501/4885KMT2A 3229/4885ASAH1 3335/4885 |
| US-20240374546-A1 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | TFAM, NDUFAB1, TUFM | MEN1 2688/4885KMT2A 3353/4885ASAH1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.